Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone

INTRODUCTION: Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated economic outcomes in men with chemotherapy-naïve metastatic castration-resistant PC (mCRPC) treated with enzalutamide or abiraterone acetate...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramaswamy, Krishnan, Lechpammer, Stanislav, Mardekian, Jack, Huang, Ahong, Schultz, Neil M., Sandin, Rickard, Wang, Li, Baser, Onur, George, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467473/
https://www.ncbi.nlm.nih.gov/pubmed/32112280
http://dx.doi.org/10.1007/s12325-020-01260-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467473/
https://www.ncbi.nlm.nih.gov/pubmed/32112280
http://dx.doi.org/10.1007/s12325-020-01260-x

Ejemplares similares